{"symbol": "SURF", "companyName": "Surface Oncology Inc", "exchange": "NASDAQ", "industry": "Research and Development in Biotechnology ", "website": "www.surfaceoncology.com", "description": "Surface Oncology is an immuno-oncology company developing next-generation antibody therapies focused on the tumor microenvironment. Its pipeline includes two wholly-owned clinical-stage programs targeting CD39 (SRF617) and IL-27 (SRF388), as well as a preclinical program focused on depleting regulatory T cells via targeting CCR8 (SRF114). In addition, Surface has two partnerships with major pharmaceutical companies: a collaboration with Novartis targeting CD73 (NZV930; Phase 1) and a collaboration with GlaxoSmithKline targeting PVRIG (SRF813; preclinical). Surface's novel cancer immunotherapies are designed to achieve a clinically meaningful and sustained anti-tumor response and may be used alone or in combination with other therapies.", "CEO": "J. Jeffrey Goater", "securityName": "Surface Oncology Inc", "issueType": "cs", "sector": "Professional, Scientific, and Technical Services", "primarySicCode": 2836, "employees": 160, "tags": ["Health Technology", "Biotechnology"], "address": "50 Hampshire St Fl 8", "address2": null, "state": "Massachusetts", "city": "Cambridge", "zip": "02139-1548", "country": "US", "phone": "16177144096"}